Imipenem

Jump to navigation Jump to search
Imipenem
File:Imipenem.svg
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
IM, IV
ATC code
Pharmacokinetic data
MetabolismRenal
Elimination half-life60 minutes
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H17N3O4S
Molar mass299.347 g/mol

WikiDoc Resources for Imipenem

Articles

Most recent articles on Imipenem

Most cited articles on Imipenem

Review articles on Imipenem

Articles on Imipenem in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Imipenem

Images of Imipenem

Photos of Imipenem

Podcasts & MP3s on Imipenem

Videos on Imipenem

Evidence Based Medicine

Cochrane Collaboration on Imipenem

Bandolier on Imipenem

TRIP on Imipenem

Clinical Trials

Ongoing Trials on Imipenem at Clinical Trials.gov

Trial results on Imipenem

Clinical Trials on Imipenem at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Imipenem

NICE Guidance on Imipenem

NHS PRODIGY Guidance

FDA on Imipenem

CDC on Imipenem

Books

Books on Imipenem

News

Imipenem in the news

Be alerted to news on Imipenem

News trends on Imipenem

Commentary

Blogs on Imipenem

Definitions

Definitions of Imipenem

Patient Resources / Community

Patient resources on Imipenem

Discussion groups on Imipenem

Patient Handouts on Imipenem

Directions to Hospitals Treating Imipenem

Risk calculators and risk factors for Imipenem

Healthcare Provider Resources

Symptoms of Imipenem

Causes & Risk Factors for Imipenem

Diagnostic studies for Imipenem

Treatment of Imipenem

Continuing Medical Education (CME)

CME Programs on Imipenem

International

Imipenem en Espanol

Imipenem en Francais

Business

Imipenem in the Marketplace

Patents on Imipenem

Experimental / Informatics

List of terms related to Imipenem


Imipenem is an intravenous beta-lactam antibiotic developed in 1985. Imipenem belongs to the subgroup of carbapenems. It is derived from a compound called thienamycin, which is produced by the bacteria Streptomyces cattleya. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. It is not active against methicillin-resistant Staphylococcus aureus, however. Imipenem and other drugs in the carbapenem class are commonly referred to as "magic bullets." Their use is typically restricted in order to avoid widespread bacterial resistance.

Method of action

Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various gram-positive and gram-negative bacteria. It remains very stable in the presence of beta-lactamase (both penicillinase and cephalosporinase) produced by some bacteria, and is a strong inhibitor of beta-lactamases from some gram-negative bacteria that are resistant to most beta-lactam antibiotics.

Co-administration with cilastatin

Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation.

Adverse effects

Common adverse drug reactions are nausea and vomiting. People who are allergic to penicillin and other beta-lactam antibiotics should not take imipenem. Imipenem can also cause seizures.

References

^ Clissold SP, Todd PA, Campoli Richards DM. Imipenem/Cilastatin: A reivew of its anti-bacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987; 33: 183-241.

See also


de:Imipenem


Template:WikiDoc Sources